7/3/2023 0 Comments Dowload free atlasti![]() Morrison GJ, Goldkorn A (2018) Development and application of Liquid Biopsies in metastatic prostate Cancer. Hench IB, Hench J, Tolnay M (2018) Liquid biopsy in clinical management of breast, lung, and Colorectal Cancer. Issa IA, Noureddine M (2017) Colorectal Cancer Screening: An Updated Review of the Available Options. Ĭrowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid Biopsy: Monitoring Cancer-Genetics in the blood. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG (2019) Hepatocellular Carcinoma Surveillance: an evidence-based Approach. The PreCar Team, Chen L, Abou-Alfa GK, Zheng B, Liu J-F, Bai J, Du L-T, Qian Y-S, Fan R, Liu X-L, Wu L, Hou J-L, Wang H-Y (2021) Genome-scale profiling of circulating cell-free DNA signatures for early detection of Hepatocellular Carcinoma in Cirrhotic Patients. Guo J, Seo Y, Ren S, Hong S, Lee D, Kim S, Jiang Y (2016) Diagnostic performance of contrast-enhanced Multidetector Computed Tomography and Gadoxetic Acid Disodium-Enhanced magnetic resonance imaging in detecting Hepatocellular Carcinoma: direct comparison and a Meta-analysis. Zhang X, Wang Z, Tang W, Wang X, Liu R, Bao H, Chen X, Wei Y, Wu S, Bao H, Wu X, Shao Y, Fan J, Zhou J (2022) Ultrasensitive and affordable assay for early detection of primary Liver Cancer using plasma cell-free DNA fragmentomics. Tzartzeva K Surveillance imaging and alpha fetoprotein for early detection of Hepatocellular Carcinoma in patients with cirrhosis: a Meta-analysis. NCCN Guidelines for Hepatobiliary Cancers. Lang H, Sotiropoulos GC, Brokalaki EI, Schmitz KJ, Bertona C, Meyer G, Frilling A, Paul A, Malagó M, Broelsch CE (2007) Survival and recurrence rates after resection for Hepatocellular Carcinoma in noncirrhotic livers. Wu X, Li J, Gassa A, Buchner D, Alakus H, Dong Q, Ren N, Liu M, Odenthal M, Stippel D, Bruns C, Zhao Y, Wahba R (2020) Circulating tumor DNA as an emerging Liquid Biopsy Biomarker for early diagnosis and therapeutic monitoring in Hepatocellular Carcinoma. ![]() Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F EASL 2017 clinical practice guidelines on the management of Hepatitis B Virus infection. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nat Rev Gastroenterol Hepatol 7(8):448–458. Yang JD, Roberts LR, Hepatocellular Carcinoma (2010) A Global View. Įl-Serag HB (2012) Epidemiology of viral Hepatitis and Hepatocellular Carcinoma. AASLD Guidelines for the treatment of Hepatocellular Carcinoma: Heimbach et Al. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero J (2018) A. In this mini review, we summarize the latest research progress of liquid biopsy based on blood cfDNA in early screening of HCC. Recently, HCC screening methods using the application of cfDNA and ctDNA have become the hot spot of early HCC diagnostics. Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are important biomarkers for liquid biopsy. Liquid biopsy is a noninvasive detection method using blood or other bodily fluids. It is urgent to find a method with high sensitivity and specificity for the early diagnosis of HCC. Ultrasound (US), computed tomography (CT), and serum alpha fetoprotein (AFP) have been used to screen HCC, but HCC is still difficult to be diagnosed in the early stage due to the low sensitivity of the above methods. Therefore, early screening for HCC is critical for clinical treatment decisions and improving the prognosis of patients. Patients with hepatocellular carcinoma (HCC) at the early stage have a better prognosis compared to HCC patients at the late stage. Hepatocellular carcinoma ranks fourth in cancer-related causes of death worldwide and second in China.
0 Comments
Leave a Reply. |